Home › Funds › DRIEHAUS CAPITAL MANAGEMENT LLC › CRNX

DRIEHAUS CAPITAL MANAGEMENT LLC position in CRNX

CRINETICS PHARMACEUTICALS IN

DRIEHAUS CAPITAL MANAGEMENT LLC reported holding 6,463,551 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$241.9M, representing 1.40% of its reported portfolio and ranking #7 among its reported holdings. DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)6.46M sh
Reported value held$241.87M
Portfolio Weight1.40%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How DRIEHAUS CAPITAL MANAGEMENT LLC's CRNX position evolved

DRIEHAUS CAPITAL MANAGEMENT LLC first disclosed a stake in CRNX in Q3 2023 at 5,132,287 shares (US$152.6M). The position peaked in Q4 2024 at 6,141,014 shares, worth US$314.0M. Across 12 filings, DRIEHAUS CAPITAL MANAGEMENT LLC increased the stake 7 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 6,463,551 shares valued at US$241.9M — an increase of 67,629 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 5.13M $152.63M New
Q4 2023 5.04M $179.32M Reduce
Q1 2024 5.23M $244.64M Add
Q2 2024 6.11M $273.76M Add
Q3 2024 5.89M $300.74M Reduce
Q4 2024 6.14M $313.99M Add
Q1 2025 6.24M $209.29M Add
Q2 2025 6.40M $184.06M Add
Q3 2025 6.48M $269.96M Add
Q4 2025 6.39M $297.35M Reduce
Q1 2026 6.40M $232.30M Hold
Q2 2026 6.46M $241.87M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRNX and 13F data

CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 37 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), Bellevue Group AG (US$98.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRNX

All CRNX fund holders →

FAQ

How long has DRIEHAUS CAPITAL MANAGEMENT LLC held CRNX?

DRIEHAUS CAPITAL MANAGEMENT LLC has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is DRIEHAUS CAPITAL MANAGEMENT LLC's current position in CRNX?

As of Q2 2026, DRIEHAUS CAPITAL MANAGEMENT LLC holds 6.46M shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $241.87M, representing 1.40% of its reported portfolio and ranking #7.

Has DRIEHAUS CAPITAL MANAGEMENT LLC been buying or selling CRNX?

In the latest 13F filing (Q2 2026), DRIEHAUS CAPITAL MANAGEMENT LLC increased its position in CRNX. The position peaked in Q4 2024 at 6.14M shares.

Which other funds hold CRNX?

Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., Bellevue Group AG, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.